Package 31722-654-31

{"route": ["ORAL"], "spl_id": "30891c38-5d64-7df7-e063-6394a90ae762", "openfda": {"upc": ["0331722654609", "0331722653602", "0331722655309"], "unii": ["4MT4VIE29P"], "rxcui": ["402246", "402247", "664741"], "spl_set_id": ["8a0c609f-e296-4925-a35c-e93a04467655"], "manufacturer_name": ["Camber Pharmaceuticals, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "1000 CAPSULE in 1 BOTTLE (31722-654-10)", "package_ndc": "31722-654-10", "marketing_start_date": "20220207"}, {"sample": false, "description": "100 BLISTER PACK in 1 CARTON (31722-654-31)  / 10 CAPSULE in 1 BLISTER PACK", "package_ndc": "31722-654-31", "marketing_start_date": "20220207"}, {"sample": false, "description": "60 CAPSULE in 1 BOTTLE (31722-654-60)", "package_ndc": "31722-654-60", "marketing_start_date": "20220207"}], "brand_name": "Atazanavir", "product_id": "31722-654_30891c38-5d64-7df7-e063-6394a90ae762", "dosage_form": "CAPSULE", "pharm_class": ["Cytochrome P450 2C8 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Cytochrome P450 3A4 Inhibitors [MoA]", "HIV Protease Inhibitors [MoA]", "Protease Inhibitor [EPC]", "UDP Glucuronosyltransferases Inhibitors [MoA]", "UGT1A1 Inhibitors [MoA]"], "product_ndc": "31722-654", "generic_name": "Atazanavir", "labeler_name": "Camber Pharmaceuticals, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Atazanavir", "active_ingredients": [{"name": "ATAZANAVIR SULFATE", "strength": "200 mg/1"}], "application_number": "ANDA212278", "marketing_category": "ANDA", "marketing_start_date": "20220207", "listing_expiration_date": "20261231"}